The mRNA Expression of PTEN, LEF1, JAK3, LC3 and p62/SQSTM1 Genes in Patients with Chronic Myeloid Leukemia

• Published in: Cardiovascular & hematological agents in medicinal chemistry Vol. 21; no. 1; p. 67
• Main Authors: Lak, Elahe Razmara, Tamaddon, Gholamhossein, Ramzi, Mani, Ranjbaran, Reza, Abedi, Elham, Sharifzadeh, Sedigheh
• Format: Journal Article
• Language: English
• Published: Netherlands 01.03.2023
• Subjects: Adult; Antineoplastic Agents - pharmacology; Apoptosis; Case-Control Studies; Child; Humans; Imatinib Mesylate - pharmacology; Imatinib Mesylate - therapeutic use; Iran; Janus Kinase 3 - metabolism; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology; Phosphatidylinositol 3-Kinases - metabolism; Phosphatidylinositol 3-Kinases - pharmacology; Phosphatidylinositol 3-Kinases - therapeutic use; PTEN Phosphohydrolase - genetics; PTEN Phosphohydrolase - metabolism; PTEN Phosphohydrolase - pharmacology; RNA, Messenger - genetics; RNA, Messenger - pharmacology; RNA, Messenger - therapeutic use; Sequestosome-1 Protein - metabolism; Iran; myeloproliferative disorder; treatment; chronic myeloid leukemia; diagnosis; Autophagy; BCR-ABL

Chronic myeloid leukemia (CML) is a progressive myeloproliferative disorder resulting from forming a chimeric BCR-ABL gene. The proteins derived from this gene can affect some genes from various signaling pathways such as PI3K/AKT/Wnt/catenin/JAK/Stat involved in proliferation, differentiation, cell...